Marker Therapeutics Inc (MRKR)

[Rkmatters]

The Conference Forum has some nice talks at Pharma Talk Radio.

I posted therein other iHubs. I may have even posted it before on this hub. It relates to TPIV as well.

Combination starting at minute 13. And then make sure you listen to 16 mins. Immunogenic intensifying immune response. Intensify it. Basically, explains the rationale for combination. I see the second talk with GSK a must listen too. You should walk away with more confidence in your investment decision IMHO.

Immuno-Oncology: Exploring the Challenges & Potential - See more at: http://theconferenceforum.org/pharma-talk-radio/#sthash.1rI7l3yJ.dpuf

Immuno-Oncology is arguably the most exciting area in the advancement of science and patient care today. However, with all research, there are plenty of challenges and to get a better understanding of this innovative approach to cancer research, we were pleased to welcome to Pharma Talk Radio, James Gulley, MD, PhD of the National Cancer Institute and Roy Baynes, MD, PhD at Merck Research Labs. Joining Drs Gulley and Baynes is Kate Woda, Director of the IO360 conference taking place at Columbia University Faculty House on June 29-30 in NYC. - See more at: http://theconferenceforum.org/pharma-talk-radio/#sthash.1rI7l3yJ.dpuf

Host:
Valerie Bowling, Producer, Pharma Talk Radio
Guests:
James Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute
Roy Baynes, MD, PhD, SVP, Global Clinical Development, Merck Research Labs
Kate Woda, Director, IO 360
The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.
- See more at: http://theconferenceforum.org/pharma-talk-radio/#sthash.1rI7l3yJ.dpuf

http://theconferenceforum.org/pharma-talk-radio/

Immuno-Oncology Drug Development: Challenges & Next Steps - See more at: http://theconferenceforum.org/pharma-talk-radio/#sthash.1rI7l3yJ.dpuf

More specifically they also address:
– Ipilumumab/Nivo/Pembro challenges
– What can we learn from the development of sipuleucel-T that may be applicable for other therapeutic vaccines?
– Challenges with the following modalities: Checkpoints, Oncolytic Virus’, Adoptive T-Cells, Cancer Vaccines
– Blinitumumab
– The more interesting agents in late stage development now in immunotherapy and its promise
– Immune related adverse events
– Adoptive cellular therapies, what is the most promising?
– Will IO become backbone therapies for cancer?
– What’s the next set of assets that are going to come out?
– What can we expect within the next year or two?
Guests:
James Gulley, MD, PhD
Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute
Axel Hoos, MD, PhD, VP, Oncology R&D, GlaxoSmithKline
The Immuno-Oncology 360° conference is scheduled for February 2-3, 2016  at the New York Academy of Medicine in NYC. For more information, please visit www.theconferenceforum.org.
- See more at: http://theconferenceforum.org/pharma-talk-radio/#sthash.1rI7l3yJ.dpuf

http://theconferenceforum.org/pharma-talk-radio/